Combined Magnetic Nanoparticle‐based MicroRNA and Hyperthermia Therapy to Enhance Apoptosis in Brain Cancer Cells
Source abstract
Abstract
A novel therapy is demonstrated utilizing magnetic nanoparticles for the dual purpose of delivering microRNA and inducing magnetic hyperthermia. In particular, the combination of lethal-7a microRNA (let-7a), which targets a number of the survival pathways that typically limit the effectiveness of hyperthermia, with magnetic hyperthermia greatly enhances apoptosis in brain cancer cells. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · RNA Interference and Gene Delivery · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering Rutgers, The State University of New Jersey 599 Taylor Road Piscataway NJ 08854 USA
Department of Chemistry and Chemical Biology Rutgers, The State University of New Jersey 610 Taylor Road Piscataway NJ 08854 USA
References (32)
Show source-provided references
1. 10.1016/S1470-2045(02)00818-510.1016/S1470-2045(02)00818-5 ↗
2. 10.1016/j.addr.2011.03.00810.1016/j.addr.2011.03.008 ↗
3. 10.1016/j.ygyno.2009.10.07810.1016/j.ygyno.2009.10.078 ↗
4. 10.1038/sj.cdd.440122910.1038/sj.cdd.4401229 ↗
5. 10.1038/sj.onc.120711410.1038/sj.onc.1207114 ↗
6. Jolly C. · J. Natl. Cancer I · 2000 · 92 · 156410.1093/jnci/92.19.1564 ↗
7. 10.4161/cbt.3.6.84610.4161/cbt.3.6.846 ↗
8. 10.2174/138161205350758510.2174/1381612053507585 ↗
9. 10.1002/anie.20130655710.1002/anie.201306557 ↗
10. 10.1379/CSC-99r.110.1379/CSC-99r.1 ↗
11. 10.1038/nrc199710.1038/nrc1997 ↗
12. 10.1016/j.cell.2009.01.00210.1016/j.cell.2009.01.002 ↗
13. 10.1158/0008-5472.CAN-10-201010.1158/0008-5472.CAN-10-2010 ↗
14. 10.1016/j.tcb.2008.07.00710.1016/j.tcb.2008.07.007 ↗
15. Lavon I. · J. Neuro‐Oncol. · 2010 · 12 · 42210.1093/neuonc/nop061 ↗
16. 10.1002/anie.20080514910.1002/anie.200805149 ↗
17. 10.1002/anie.20130224510.1002/anie.201302245 ↗
18. 10.1021/nn101638u10.1021/nn101638u ↗
19. 10.1088/0022-3727/46/12/12500610.1088/0022-3727/46/12/125006 ↗
20. 10.1039/b711962c10.1039/b711962c ↗
21. 10.1016/j.jconrel.2006.02.00910.1016/j.jconrel.2006.02.009 ↗
22. 10.1016/j.addr.2011.08.00210.1016/j.addr.2011.08.002 ↗
23. 10.1016/j.jconrel.2006.04.01410.1016/j.jconrel.2006.04.014 ↗
24. 10.1016/j.cell.2011.08.03310.1016/j.cell.2011.08.033 ↗
25. 10.1007/s11060-010-0286-610.1007/s11060-010-0286-6 ↗
26. 10.1101/gad.13.22.290510.1101/gad.13.22.2905 ↗
27. 10.1158/1535-7163.MCT-11-020510.1158/1535-7163.MCT-11-0205 ↗
28. 10.1212/WNL.54.6.135710.1212/WNL.54.6.1357 ↗
29. Ito A. · Cancer Immunol. Immun. · 2003 · 52 · 8010.1007/s00262-002-0335-x ↗
30. 10.1016/j.jbiotec.2010.01.01210.1016/j.jbiotec.2010.01.012 ↗
31. Silva A. C. · Int. J. Nanomed. · 2011 · 6 · 591
32. 10.1074/jbc.M31016420010.1074/jbc.M310164200 ↗